CC

Current Cancer Drug Targets

Current Cancer Drug Targets is a journal focused on cancer drug targets. It has ISSN 1568-0096 (Print) and 1873-5576 (Online), a current Impact Factor of 3.5, and indexing in Scopus, SCI Expanded, and MEDLINE/PubMed. The journal offers online manuscript submission and includes open access articles.

Looking to publish in Current Cancer Drug Targets? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 3.5
Quartile Q2
Open Access Type Hybrid
ISSN 1568-0096
eISSN 1873-5576
Invitation Only No
Cost Range Research articles: US $490; short communications/letters: US $200; reviews and mini-reviews: US $290. Optional Gold Open Access: US $3695 per article for general submissions and US $1900 for thematic issues. Optional Quick Track fee: US $4845 per article.

Submission Instructions

Current Cancer Drug Targets accepts the following article types. Click on an article type to view submission instructions.

Review Articles

Cover Letter A signed copyright letter must be submitted with the manuscript by the corresponding author on behalf of all co-authors. The copyright letter must reflect approval for submission and publication by all co-authors.
Abstract A structured abstract is required for Review Articles. Abstract must not exceed 250 words. The abstract must be structured. Explicit subheadings in bold are required in the abstract.
Manuscript Review Articles must be 6000–10000 words, excluding figures, structures, photographs, schemes, and tables. Review Articles must be organized into Title, Title page, Structured Abstract, Graphical Abstract, Keywords, Text Organization, Conclusion, List of Abbreviations, Consent for Publication, Availability of Data and Materials, Funding, Conflict of Interest, Acknowledgements, References, Appendices, Figures/Illustrations, Chemical Structures, Tables, and Supportive/Supplementary Material. The manuscript must include a graphical abstract, 6 to 8 keywords, a List of Abbreviations, and disclosure sections including Conflict of Interest, Funding, Availability of Data and Materials, Acknowledgements, Supportive/Supplementary Material, and AI use where applicable.
References Review Articles must include 100 or more references. References must be submitted preferably in ACS or Vancouver style. References must be cited numerically in square brackets in the text and the bibliography must be complete and fully formatted before submission.
Figures & Tables Figures and tables must be embedded in the manuscript text at the appropriate place, while figure files must also be provided separately. Figures must be numbered consecutively with legends or captions, and tables must be numbered sequentially and include a self-explanatory title or caption.
Reformat to Current Cancer Drug Targets using Livewrite Premium

Mini-Reviews

Cover Letter A signed copyright letter must be submitted with the manuscript by the corresponding author.
Abstract Abstract must not exceed 250 words. Abstract must use explicit bold subheadings.
Manuscript Mini-Reviews must be 3000-6000 words excluding figures, structures, photographs, schemes, and tables. Manuscript must include a graphical abstract, 6 to 8 keywords, an Authors' Contribution paragraph, a CRediT Author Statement, a conflict of interest statement, a Supportive/Supplementary Material section before the references, and disclosure of significant AI tool use.
References Mini-Reviews must include 75 or more references. References must be submitted preferably in ACS or Vancouver style. References must be cited in the text using square-bracketed numbers and listed as a complete, fully formatted bibliography, excluding abstracts, unpublished data, and personal communications.
Figures & Tables Figures and tables must be embedded in the text at their appropriate placement, although figure files must also be provided separately. Figures and tables must be numbered consecutively in order of citation and each table must include a self-explanatory title or caption while each figure must include a legend or caption.
Reformat to Current Cancer Drug Targets using Livewrite Premium

Systematic Reviews

Cover Letter A signed copyright letter must be submitted by the corresponding author on behalf of all co-authors. The cover letter must include a declaration of approval and consent-to-disclose when the manuscript contains identifiable individual data or images.
Abstract A structured abstract is required for Systematic Reviews. Abstract must not exceed 250 words. The abstract must be structured using explicit subheadings. The structured abstract must state the purpose of the study, details of the participants, measurements, methods, main findings, and conclusion, and a registered systematic review must include the registration number as the last line.
Manuscript Systematic Reviews must be 4000-6000 words excluding figures, structures, photographs, schemes, and tables. Systematic reviews must address the methods used for selecting, locating, extracting, and synthesizing data. The manuscript must include a graphical abstract, 6 to 8 keywords, an Authors' Contribution paragraph, a CRediT Author Statement, a conflict of interest statement, a summary statement before the references reflecting the conflict disclosure form, a section headed 'Supportive/Supplementary Material' before the references, and AI-use disclosures in the Materials and Methods or similar section when applicable.
References Systematic Reviews must include 100 or more references. References must be submitted preferably in ACS or Vancouver style. References must be cited in the text using square-bracketed numbers and listed as complete and fully formatted entries, excluding abstracts, unpublished data, and personal communications.
Figures & Tables Figures and tables must be embedded in the manuscript text at their appropriate placements, although figure and illustration files must also be provided separately for submission. Figures and tables must be numbered consecutively in the order of citation, each figure must include a legend or caption, and each table must include a self-explanatory title or caption.
Reformat to Current Cancer Drug Targets using Livewrite Premium

Research Articles

Cover Letter A signed copyright letter must be submitted with the manuscript by the corresponding author on behalf of all co-authors.
Abstract A structured abstract is required for Research Articles. Abstract must not exceed 250 words. Abstract must be structured with explicit subheadings. Structured abstract must state the purpose of the study, details of the participants, measurements, methods, main findings, and conclusion.
Manuscript Research Articles must be 4000-6000 words excluding figures, structures, photographs, schemes, and tables. Main text must be organized as Introduction, Materials and Methods, Results, Discussion, and Conclusion. Manuscript must include a graphical abstract, 6 to 8 keywords, a List of Abbreviations, and declarations for Availability of Data and Materials, Funding, Conflict of Interest, Acknowledgements, and Supportive/Supplementary Material, and authors who use AI tools for images or data collection and analysis must disclose this use in the Materials and Methods or similar section.
References Research Articles must include 75 or more references. References must be submitted preferably in ACS or Vancouver style. References must be numbered in square brackets in the text and listed as complete and fully formatted entries, and abstracts, unpublished data, and personal communications must not be included in the references section.
Figures & Tables Figures and tables must be embedded in the text at their appropriate placement, while figure and chemical structure files must also be provided separately. Figures and tables must be numbered consecutively in the order of citation and each table must include a self-explanatory title or caption.
Reformat to Current Cancer Drug Targets using Livewrite Premium

Randomized Drug Clinical Trial Studies

Cover Letter A signed copyright letter must be submitted with the manuscript by the corresponding author on behalf of all co-authors.
Abstract Abstract must not exceed 250 words. Abstract must be structured using explicit bold subheadings.
Manuscript Manuscript must be 4000–6000 words excluding figures, structures, photographs, schemes, and tables. Manuscript must clearly state the objective or hypothesis, design and methods including setting, dates, participants or data sources and selection criteria, interventions, main outcome measures, main results, a comment section addressing context and limitations, conclusions, and a 'Randomization and Masking' section within Methods. Manuscript must include a graphical abstract, 6 to 8 keywords, a conflict of interest statement, an Authors' Contribution section, a CRediT Author Statement, a 'Supportive/Supplementary Material' section before the references, and AI-use disclosure in the Materials and Methods or similar section when applicable.
References Manuscript must include 50 or more references. References must be submitted preferably in ACS or Vancouver style. References must be numbered in square brackets in the text and listed as complete, accurate, fully formatted entries, excluding abstracts, unpublished data, and personal communications.
Figures & Tables Figures and chemical structures must be provided as separate files, while figures and tables must also be embedded in the manuscript at the appropriate placement. Figures and tables must be numbered consecutively in the order of appearance, each figure must have a legend, each table must have a self-explanatory title or caption, and each must be cited in the text.
Reformat to Current Cancer Drug Targets using Livewrite Premium

Meta-Analyses

Cover Letter A signed copyright letter must be submitted by the corresponding author on behalf of all co-authors. The corresponding author must have the approval of all other listed authors for submission and publication of all versions of the manuscript.
Abstract A structured abstract is required for Meta-Analyses. Abstract must not exceed 250 words. The abstract must be structured using explicit subheadings. The structured abstract must state the purpose of the study, details of the participants, measurements, methods, main findings, and conclusion.
Manuscript Meta-Analyses must be reported according to PRISMA guidelines, and meta-analyses of observational studies in epidemiology must also follow MOOSE guidelines. The manuscript must include a graphical abstract, 6 to 8 keywords, an Authors' Contribution section, a CRediT Author Statement, a conflict of interest statement, a summary conflict statement before the references, a Supportive/Supplementary Material section before the references, and disclosure of significant AI tool use.
References References must be submitted preferably in ACS or Vancouver style. References must be cited in the text using square-bracketed numbers and abstracts, unpublished data, and personal communications must not be included in the reference list.
Figures & Tables Figures and tables must be embedded in the text, although figure files must also be provided separately. Figures and tables must be numbered consecutively in the order of appearance, each figure must include a legend or caption, and each table must include a self-explanatory title or caption.
Reformat to Current Cancer Drug Targets using Livewrite Premium

Short Communications

Cover Letter A signed copyright letter must be submitted by the corresponding author on behalf of all co-authors.
Abstract Abstract must not exceed 250 words. Abstract must use explicit subheadings in bold.
Manuscript Short Communications must be 2000-3000 words, excluding figures, structures, photographs, schemes, and tables. Manuscript must include a graphical abstract, 6 to 8 keywords, a conflict of interest statement, an Authors' Contribution paragraph, a CRediT Author Statement, a Supportive/Supplementary Material section before the references, and disclosure of significant AI tool use.
References Short Communications must include 25 or more references. References should be submitted preferably in ACS or Vancouver style. References must be cited numerically in square brackets and must not include abstracts, unpublished data, or personal communications.
Figures & Tables Figures and tables must be embedded in the text, while figures and chemical structures must also be provided as separate files. Figures and tables must be numbered consecutively in the order of appearance and each table must include a self-explanatory title or caption.
Reformat to Current Cancer Drug Targets using Livewrite Premium

Letters

Cover Letter A signed copyright letter must be submitted by the corresponding author on behalf of all co-authors. The corresponding author must submit the copyright letter on behalf of all co-authors.
Abstract An abstract is required for Letters. Abstract must not exceed 250 words. Abstract must use explicit subheadings in bold.
Manuscript Letters must be 3000-4000 words excluding figures, structures, photographs, schemes, and tables. Main text must follow the Title page and Abstract and be organized into Introduction, Materials and Methods, Results, Discussion, Conclusion, Ethics Approval and Consent to Participate, Human and Animal Rights, Conflict of Interest, Acknowledgements, and References. A graphical abstract, 6 to 8 keywords, an Authors' Contribution section, a CRediT Author Statement, a Supportive/Supplementary Material section before the References, and AI-use disclosures in the manuscript are required.
References Letters must include 40 or more references. References must be submitted preferably in ACS or Vancouver style. References must be cited in the text with numbers in square brackets and listed as complete and fully formatted entries, excluding abstracts, unpublished data, and personal communications.
Figures & Tables Figures and tables must be embedded in the text file, while figure files must also be provided separately. Figures and tables must be numbered consecutively in the order of citation and each table must include a self-explanatory title or caption.
Reformat to Current Cancer Drug Targets using Livewrite Premium

Case Reports

Cover Letter A signed copyright letter must be submitted by the corresponding author on behalf of all co-authors.
Abstract Abstract must not exceed 250 words. Abstract must use explicit bold subheadings.
Manuscript Case Reports must be 1500–2500 words excluding figures, structures, photographs, schemes, and tables. The manuscript must include 6 to 8 keywords, a graphical abstract with text not exceeding 30 words, conflict of interest and authors' contribution sections, a CRediT author statement, a Supportive/Supplementary Material section before the references, and disclosure of significant AI tool use in the work.
References Case Reports must include 40 or more references. References must be submitted preferably in ACS or Vancouver style. References must be cited in the text with numbers in square brackets and must exclude abstracts, unpublished data, and personal communications from the reference list.
Figures & Tables Figures and tables must be embedded in the text at their appropriate placement, although figure files must also be provided separately. Figures and tables must be numbered consecutively in order of appearance, each figure must include a caption, and each table must include a self-explanatory title or caption.
Reformat to Current Cancer Drug Targets using Livewrite Premium

Recent Publications

Screening of Demethylation-related Biomarkers and Exploration of Regulatory Mechanisms in Esophageal Cancer Patients Based on Machine Learning and Mendelian Randomization

Yi Sheng, Jie Ma, Yang Li, Zihuan Yin, Xukun Gao, Ruixing Luo, Boxiang Sheng, Xueying Zhu, Renquan Zhang

10.2174/0115680096448097260417093740
View Publication

CXCR4 Facilitates Osteosarcoma Progression through MMP9-Mediated Cell Migration and Matrix Degradation

Hanyong Zhang, Mengchang Xu, Yan Jiang, Jia Luo, Qin Tan, Ziyu Huang, Wenchang Shi, Ruiche Shi, Binsheng He

10.2174/0115680096459805260518192517
View Publication

Scorpion Venom-Derived Voltage-Gated Potassium Channel Blocker Peptides: A Cutting-Edge Therapeutic Frontier in Breast Cancer Research and Beyond

Fatemeh Kazemi-Lomedasht, Mohammad Hosein Ghaffari, Mohammad Amir Esmaeili, Seyedeh Narges Fatemi, Zohre Eftekhari

10.2174/0115680096411088251126054847
View Publication

Rare ALK–IR (Intergenic Region) Rearrangement in a Patient with Non-Small Cell Lung Cancer: A Case Report

Qingtao Ni, Chi Pan, Guangzhi Sun, Jianping Song, Quan Chen, Peng Wang

10.2174/0115680096433153251111154000
View Publication

AAV-HOTAIR Delivery in Colorectal Cancer Cells: Preliminary Insights into Gene Silencing and Epigenetic Influences

Mohammed Y. I. Al-Hamadani, Firas H. Khathayer, Mohammed N. Al-Khafaf, Haitham A. Rajab, Wael M. El-Sayed

10.2174/0115680096443654260330053221
View Publication

Frequently asked questions

How long does it take to publish?

Quick Track allows online publication within 2 weeks of receipt of final approved galley proofs, with total publication time from first receipt to online publication of 10 weeks, subject to acceptance and author modifications within one week. Authors are usually requested to resubmit revised papers within 15 days, and revision time may vary from 1 to 4 weeks.

Reformat to Current Cancer Drug Targets using Livewrite Premium

Is a cover letter required?

A signed copyright letter must be submitted with the manuscript by the corresponding author on behalf of all co-authors.

Reformat to Current Cancer Drug Targets using Livewrite Premium

What are the publication costs?

Standard publication charges are US $490 for research articles, US $200 for short communications and letters, and US $290 for reviews and mini-reviews. Optional Gold Open Access costs US $3695 per article for general submissions and US $1900 for thematic issues.

Reformat to Current Cancer Drug Targets using Livewrite Premium

Research Topics

Cancer Mechanisms and Therapy Cancer, Hypoxia, and Metabolism Cancer Research and Treatments Cancer, Lipids, and Metabolism Histone Deacetylase Inhibitors Research Cancer Immunotherapy and Biomarkers Epigenetics and DNA Methylation Cancer-related Molecular Pathways PI3K/AKT/mTOR signaling in cancer Ferroptosis and cancer prognosis Ubiquitin and proteasome pathways Cancer Treatment and Pharmacology Protein Degradation and Inhibitors Diverse Scientific and Economic Studies Cancer Cells and Metastasis MicroRNA in disease regulation HER2/EGFR in Cancer Research Computational Drug Discovery Methods Cancer therapeutics and mechanisms Lung Cancer Treatments and Mutations Nanoparticle-Based Drug Delivery 14-3-3 protein interactions Cancer-related molecular mechanisms research Immunotherapy and Immune Responses Synthesis and biological activity

Related Journals

TA
Therapeutic Advances in Medical Oncology SAGE Publishing
NR
Nature Reviews Clinical Oncology NATURE PORTFOLIO
CI
Cancer Imaging BioMed Central
GC
Gastric Cancer Springer Science+Business Media
JO
JCO Oncology Practice LIPPINCOTT WILLIAMS & WILKINS
CO
Current Oncology Multidisciplinary Digital Publishing Institute